Brought to you by 
AstraZeneca, Cambridge Antibody enter inflammation alliance
Dec 2004
Executive Summary
AstraZeneca and Cambridge Antibody Technology have entered into a five-year co-funded and co-managed project to discover and develop monoclonal antibodies to treat inflammatory (including respiratory) diseases.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- R+D and Marketing-Licensing
- Includes Equity
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca, Cambridge Antibody enter inflammation alliance
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice